Seongnam-si, South Korea

Mi Young Cha

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 9.8

ph-index = 4

Forward Citations = 36(Granted Patents)


Location History:

  • Kyungki-do, KR (2004)
  • Suwon-si, KR (2011)
  • Seongnam-si, KR (2009 - 2017)

Company Filing History:


Years Active: 2004-2017

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):

Title: Mi Young Cha: Innovator in Pharmaceutical Chemistry

Introduction

Mi Young Cha is a prominent inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of seven patents to his name, Cha's work focuses on innovative solutions for treating various diseases.

Latest Patents

Among his latest patents, Cha has developed fused pyrimidine derivatives that inhibit tyrosine kinase activity. This invention relates to a novel fused pyrimidine derivative that exhibits inhibitory activity for tyrosine kinases. The pharmaceutical composition derived from this invention aims to prevent or treat cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases.

Career Highlights

Cha has worked with notable companies in the pharmaceutical industry, including Hanmi Science Co., Ltd. and Hanmi Holdings Co., Ltd. His expertise in drug development and innovative chemistry has positioned him as a key figure in his field.

Collaborations

Some of his coworkers include Maeng Sup Kim and Mi Ra Kim, who have collaborated with him on various projects. Their combined efforts have contributed to advancements in pharmaceutical research and development.

Conclusion

Mi Young Cha's innovative work in the field of pharmaceutical chemistry has led to significant advancements in medical treatments. His contributions continue to impact the industry positively, showcasing the importance of research and innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…